MTDH-SND1 Interaction Is Crucial for Expansion and Activity of Tumor-Initiating Cells in Diverse Oncogene- and Carcinogen-Induced Mammary Tumors  by Wan, Liling et al.
Cancer Cell
ArticleMTDH-SND1 Interaction Is Crucial for Expansion
and Activity of Tumor-Initiating Cells in Diverse
Oncogene-andCarcinogen-InducedMammaryTumors
Liling Wan,1 Xin Lu,1,6 Salina Yuan,1 Yong Wei,1 Feng Guo,2 Minhong Shen,1 Min Yuan,1 Rumela Chakrabarti,1
Yuling Hua,1 Heath A. Smith,1 Mario Andres Blanco,1,7 Marina Chekmareva,3 Hao Wu,4 Roderick T. Bronson,5
Bruce G. Haffty,4 Yongna Xing,2 and Yibin Kang1,4,*
1Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
2McArdle Laboratory, Department of Oncology, University of Wisconsin-Madison, School of Medicine and Public Health, Madison,
WI 53706, USA
3Pathology and Laboratory Medicine, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ 08903, USA
4Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA
5Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
6Present address: Departments of Cancer Biology, GenomicMedicine, and Experimental Radiation Oncology and Institute of Applied Cancer
Science, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
7Present address: Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
*Correspondence: ykang@princeton.edu
http://dx.doi.org/10.1016/j.ccr.2014.04.027SUMMARYThe Metadherin gene (MTDH) is prevalently amplified in breast cancer and associated with poor prognosis;
however, its functional contribution to tumorigenesis is poorly understood. Using mouse models represent-
ing different subtypes of breast cancer, we demonstrated that MTDH plays a critical role in mammary tumor-
igenesis by regulating oncogene-induced expansion and activities of tumor-initiating cells (TICs), whereas it
is largely dispensable for normal development. Mechanistically, MTDH supports the survival of mammary
epithelial cells under oncogenic/stress conditions by interacting with and stabilizing Staphylococcal
nuclease domain-containing 1 (SND1). Silencing MTDH or SND1 individually or disrupting their interaction
compromises tumorigenenic potential of TICs in vivo. This functional significance of MTDH-SND1 interaction
is further supported by clinical analysis of human breast cancer samples.INTRODUCTION
Cancer is characterized by rampant genetic and epigenetic alter-
ations. Recurrent DNA copy number alterations often indicate
the presence of key drivers of cancer at the affected loci. We pre-
viously identified Metadherin (MTDH; also called AEG1, LYRIC)
as a prometastasis gene that resides in 8q22, a frequently ampli-
fied genomic locus linked to poor relapse-free survival of breast
cancer (Hu et al., 2009). Notably, overexpression of MTDH is
observed in more than 40% of primary breast tumors and is an
independent factor for poor prognosis (Hu et al., 2009). WhatSignificance
Our finding that MTDH is required for the expansion and func
selection pressure to overexpress MTDH in diverse breast tu
but not mammary stem cells, suggesting that it is different f
and cancerous stem cells. The functional dependency of MT
the observation that systemic deletion of MTDH is well tolerate
may offer an opportunity to control tumor initiation, recurrence
minimal impact on normal tissues.
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is unclear and the functional significance of MTDH in normal
development and tumorigenesis remains poorly understood.
Recent studies using cell culture or xenograft models have
implicated MTDH in several cancer-related processes, including
proliferation, cell death, invasion, and angiogenesis (Emdad
et al., 2013), although the underlying mechanistic understanding
of MTDH in these processes remains limited to date. In breast
cancer, MTDH was postulated to be a transmembrane protein
that mediates the adhesion of cancer cells to the lung endothe-
lium (Brown and Ruoslahti, 2004). In certain cancer types, MTDHtion of both luminal and basal breast TICs underscores the
mor subtypes. We also show that MTDH is crucial for TICs
rom many cell fate determinants that regulate both normal
DH on its conserved interaction with SND1, together with
d in mice, suggest that targeting the MTDH-SND1 complex
, and metastasis by preventing the expansion of TICs, with
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phosphoinositide 3-kinase/protein kinase B and nuclear fac-
tor k-light-chain-enhancer of activated B cells (Emdad et al.,
2013). However, how MTDH regulates these pathways remains
elusive. Although evolutionarily conserved in higher vertebrates,
MTDH contains no recognizable functional domain, rendering
the understanding of its biological function challenging. Multiple
groups have identified several MTDH-binding partners, including
promyelocytic leukemia zinc finger, BCCIPa, and Staphylo-
coccal nuclease domain-containing 1 (SND1; Wan and Kang,
2013). However, whether and how the interactions with these
proteins mediate the function of MTDH is largely unknown.
Breast cancer is a heterogeneous disease that can be broadly
classified into luminal and basal-like subtypes based on gene
expression profiles (Perou et al., 2000). It has been speculated
that different oncogenic signaling may target different cells of
origin, thus leading to the formation of different subtypes of
breast cancer. However, the origin, identity, and regulation
of tumor-initiating cells (TICs) in different oncogene-induced
mammary tumors remain poorly characterized. Autochthonous
tumorigenesis in mice offers great models for tracking the early
changes during tumor initiation and for investigating the role of
a gene of interest in mediating the transformation and expansion
of TICs. In this study, we investigate the function of MTDH in
breast cancer initiation and progression.
RESULTS
Mtdh-Knockout Mice Were Viable and Grossly
Indistinguishable from Wild-Type Mice
To generate Mtdh-knockout (KO) mice, we screened the Bay
Genomics gene trap database and selected ESC line XB780,
which contains an insertion into the second intron of Mtdh that
results in premature termination of transcription (Figure 1A). In-
jection of XB780 ES cells into blastocysts generated chimeric
mice with subsequent confirmation of germline transmission
(Figure S1A available online). Crosses between Mtdh hetero-
zygous (Mtdh+/) mice gave rise to offspring at the Mendelian
ratio. Mtdh homozygous KO (Mtdh/) embryos showed wide-
spread LacZ activity (Figure 1B), suggesting ubiquitous Mtdh
expression in many embryonic organs. In adult mice, MTDH
was also detected in a variety of tissues in wild-type (WT,
Mtdh+/+) and Mtdh+/ mice, while undetectable in Mtdh/
mice (Figure S1B), confirming that the gene-trapped allele
completely abolished Mtdh expression. Mtdh/ mice were
viable, fertile, and displayed no obvious abnormalities when
monitored for up to 2 years (data not shown).
MTDH was also detected in normal mammary epithelial cells
(MECs) and the expression levels correlated with Mtdh genetic
status (Figure 1C). To assess the influence of MTDH deficiency
in postnatal mammary gland development, whole mounts of
inguinal mammary fat pads from WT and KO virgin mice were
examined (Figure S1C). Except for a transient delay in ductal
outgrowth of mammary glands from 3- and 5-week-old KO
mice as compared to WT littermates, we did not observe signif-
icant differences in branchingmorphogenesis at later time points
(Figure S1D) or during pregnancy and lactation (Figures S1E and
S1F). The largely comparable mammary epithelium in WT and
Mtdh/ mice starting at puberty therefore allows us to useMtdh/ mice to examine the necessity of MTDH for mammary
tumor formation.
Mtdh KO Inhibits the Formation and Metastasis of
Luminal Mammary Tumors
To dissect the roles of MTDH during autochthonous mammary
tumor progression, we first used the MMTV-PyMT and MMTV-
ErbB2 transgenic models, both of which develop luminal adeno-
carcinoma with a high incidence of lung metastasis. In the
aggressive MMTV-PyMT model, mammary tumors occurred as
early as 42 days of age, and by day 63, 50% of Mtdh+/+ mice
developed tumors (Figure 1D). In contrast, the first palpable
tumor was detected in the Mtdh/ group at day 50, and 50%
of these mice developed tumors only after 80 days. The delay
in tumor occurrence was further supported by a greater number
of tumor-free mammary glands inMtdh/mice as compared to
WT control (Figure 1E). Consistently, the total tumor burden of
PyMT;Mtdh+/ and PyMT;Mtdh/ mice was reduced to 54%
and 10% of that of WT control, respectively (Figure 1F). Further-
more, PyMT;Mtdh/ mice had significantly fewer (Figure 1G)
and smaller (p < 0.05, data not shown) metastatic nodules.
The difference in tumor formation was even more prominent in
the MMTV-ErbB2 model, in which tumorigenesis occurs after
long latency. Whereas almost all ErbB2;Mtdh+/+ mice developed
tumors by 300 days of age, more than 60% of ErbB2;Mtdh/
mice had no tumors (Figures 1H and 1I). Even when monitored
for up to 18 months, 30% of ErbB2;Mtdh/ mice (n = 68) still
remained completely tumor-free, whereas all ErbB2;Mtdh+/+
mice (n = 61) had either died or reached the morbidity criteria
for euthanization (p < 0.0001). Lungmetastasis was also severely
impaired in ErbB2;Mtdh/ mice (Figures 1J and 1K).
The difference in mammary tumor formation was not due to
the differential induction of oncogenes because the expression
of PyMT (Figure S1G) and ErbB2 (Figures S1H and S1I) was com-
parable between WT and KO mammary glands or tumors. In
addition, the activation of ErbB2, as indicated by its phosphory-
lation, was not affected (Figures S1H and S1I). Furthermore,
MTDH protein levels were elevated in PyMT- and ErbB2-driven
tumors as compared to age-matched normal controls (Figures
S1J and S1K), suggesting that high levels of MTDH may confer
growth advantage to MECs during tumorigenesis.
Mtdh KO Restrains the Formation of Basal-like and
Mixed Subtypes of Mammary Tumors
We further expanded our investigation of MTDH in tumor for-
mation to the MMTV-Wnt model, which develops tumors that
exhibit mammary stem cell (MaSC)-like gene expression profiles
and resemble the basal subtype of human breast cancer
(Herschkowitz et al., 2007). While virtually all Wnt;Mtdh+/+ mice
succumbed to cancer at 300 days of age, no tumors were
detected in 35% of Wnt;Mtdh+/ and 62% of Wnt;Mtdh/
mice (Figure 1L). The multiplicity of tumors was also highly
dependent on the gene dosage ofMtdh (Figure 1M). These phe-
notypes markedly resembled what we observed in the luminal
tumor models. To broaden our analysis, we induced mammary
carcinogenesis using combined treatment of medroxyproges-
terone acetate (MPA) and 7, 12-dimethylbenzanthracene
(DMBA) (Figure 1N), which resulted in the formation of mammary
tumors with histological characteristics of adenocarcinoma,Cancer Cell 26, 92–105, July 14, 2014 ª2014 Elsevier Inc. 93
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Figure 1. Systemic Deletion of Mtdh Inhibits Mammary Tumor Formation and Metastasis
(A) Schematic representation ofWT andmutantMtdh allele. Green boxes represent exons 1–12. Primers (F, forward; R, reverse) used for genotyping are indicated
above the corresponding genomic sequences.
(B) LacZ expression in WT and KO embryo at day 10.5, depicted with X-gal staining.
(C) MTDH protein immunobloting in MECs freshly dissociated from 8-week-old female mice with indicated Mtdh genotype.
(D) Kinetics of mammary tumor onset in MMTV-PyMT females of indicated Mtdh genotypes. Mtdh+/+ (n = 13), Mtdh+/ (n = 26), and Mtdh/ (n = 30).
(E) Percentage of tumor-free mammary glands at indicated ages in the same cohort of mice as in (D).
(F) Total tumor burden of PyMT;Mtdh+/+, PyMT;Mtdh+/, and PyMT;Mtdh/ cohorts evaluated at indicated age. Statistical comparison was done between
Mtdh+/+ and Mtdh/ groups. Data represent mean ± SEM (n > 20).
(G) Number of lung metastatic nodules in PyMT;Mtdh+/+ (n = 15), PyMT;Mtdh+/ (n = 11), and PyMT;Mtdh/ (n = 14) animals. Error bars represent the 5th to 95th
percentiles.
(H) Kinetics of mammary tumor onset in MMTV-ErbB2 mice of the indicated genotypes. Mtdh+/+ (n = 22), Mtdh+/ (n = 31), and Mtdh/ (n = 27).
(I) Percentage of mice from same cohorts as in (H) bearing indicated number of tumors at 300 days of age.
(J) Incidence of lung metastasis in tumor-bearing MMTV-ErbB2 mice from Mtdh+/+ (n = 30) and Mtdh/ (n = 23) groups.
(K) Number of metastatic lesions per lung section in the same cohorts of mice from (J). Error bars represent the 5th to 95th percentiles.
(L) Kinetics of mammary tumor onset in MMTV-Wnt mice of the indicated genotypes. Mtdh+/+ (n = 31), Mtdh+/ (n = 48), and Mtdh/ (n = 31).
(M) Percentage of mice from same cohorts as in (L) bearing indicated number of tumors at 300 days of age.
(N) Kinetics of mammary tumor onset in mice with indicatedMtdh genotype treated with MPA and DMBA as indicated (top). Tumor latency was recorded as days
after first DMBA treatment. Mtdh+/+ (n = 19), Mtdh+/ (n = 13), and Mtdh/ (n = 10).
(O) Percentage of mice from same cohorts as in (N) bearing indicated number of tumors at 4 months of age.
Statistics: (D, H, L, and N) log rank test. (E, I, J, M, and O) Chi-square test. (G and K) Mann-Whitney test. (F) Student’s t test. ***p < 0.001, **p < 0.01, *p < 0.05. See
also Figure S1.
Cancer Cell
MTDH-SND1 Interaction in Breast Cancer Initiation
94 Cancer Cell 26, 92–105, July 14, 2014 ª2014 Elsevier Inc.
Cancer Cell
MTDH-SND1 Interaction in Breast Cancer Initiationadenosquamous carcinoma and adenomyoepithelioma carci-
noma (Yin et al., 2005). Again, Mtdh/ females showed mark-
edly attenuated tumor susceptibility after MPA/DMBA treatment
(Figures 1N and 1O).
Mtdh KO Impairs the Expansion and Activities of
Oncogene-Induced Basal and Luminal TICs
The dramatic effect ofMtdh deletion on mammary tumor forma-
tion prompted us to investigate early events during tumorigen-
esis. To this end, we examined whole mounts (Figure 2A, top)
and hematoxylin and eosin-stained sections (Figure 2A, bottom)
of mammary glands from different tumor models at preneo-
plastic stages. Both the PyMT and Wnt oncogenes induced
extensive hyperplasia as early as 4 weeks in Mtdh+/+ mice;
however, Mtdh/ glands exhibited significantly fewer and
smaller hyperplasia foci mingled with normal ductal structures.
MMTV-ErbB2 mice have the longest tumor latency, and this
corresponds to significantly delayed and the least severe hyper-
plasia. Whole mount analysis of mammary glands from 6-month-
old tumor-free MMTV-ErbB2 females revealed close to 100%
incidence of hyperplasia in Mtdh-positive mice, whereas only
20% of those from ErbB2;Mtdh/mice were mildly hyperplasic
(Figures S2A and S2B).
These severely impaired preneoplastic changes in Mtdh/
glands may suggest a defect in the expansion of transformed
MECs. To examine oncogene-induced changes in the cellular
composition of mammary glands, we profiled preneoplastic
mammary glands using CD24, CD29 (b1 integrin) and CD61 (b3
integrin), which have been previously used to resolve luminal
and basal mammary epithelial subsets (Asselin-Labat et al.,
2007; Shackleton et al., 2006). Compared to normal glands,
PyMT preneoplastic tissues displayed a drastic expansion of
the LinCD24+CD29low luminal subset (CD24+CD29low; Figures
2B and 2C), consistent with previous reports of ‘‘luminal-like’’
gene expression profiles (Herschkowitz et al., 2007). In contrast,
the percentage of LinCD24+CD29high (CD24+CD29hi) basal
population, which enriches for MaSCs, was markedly increased
in preneoplastic tissues from Wnt mammary glands (Figures 2B
and 2D), as previously noted (Shackleton et al., 2006), suggest-
ing that this population represents a key cell target for trans-
formation in this model. Intriguingly, these oncogene-specific
perturbations of the epithelial hierarchy were compromised by
Mtdh loss, as evidenced by (1) the lack of CD24+CD29low luminal
subset expansion in PyMT;Mtdh/glands (Figures 2B and 2C),
and (2) a significant decrease in the expansion of the CD24+
CD29hi basal subset in Wnt;Mtdh/ glands (Figures 2B and
2D) compared to WT counterparts. PyMT- or Wnt-induced
hyperplastic glands in Mtdh+/+ mice did not exhibit a selective
expansion of CD61+ population as compared to normal glands
(Figures S2C and S2D, compare orange bars). However, we
noticed that the percentage of CD61+ cells, which were more
capable of forming mammospheres than CD61 cells (Fig-
ure S2E), was significantly decreased in Wnt;Mtdh/ glands
as compared to Wnt;Mtdh+/+ glands (Figures S2C and S2D,
compare WT versus KO).
To test whetherMtdh/ preneoplastic glands indeed contain
fewer TICs, we dissociated primaryMECs (pMECs) fromMtdh+/+
and Mtdh/ preneoplastic glands and performed in vitro
mammosphere formation assays. Mtdh/ pMECs formed adecreased number of spheres across multiple tumor models
(Figure 2E). Moreover, when orthotopically transplanted into
WT recipient mice, PyMT;Mtdh/ pMECs contained substan-
tially fewer tumor-repopulating cells in vivo as revealed by
reduced tumor incidence when a series of diluting numbers
were tested (Figure 2F).
We further asked whether PyMT-induced TICs exist in the
expanded luminal population. Sorted luminal and basal pMECs
from preneoplastic glands of PyMT mice were transplanted
in vivo. Tumors were detected at high frequency in mice that
received luminal but not basal cells (Figure 2G), suggesting
PyMT-induced preneoplastic TICs were copurified with luminal
subset of MECs. Importantly, when the tumorigenic capabilities
of luminal cells from PyMT;Mtdh+/+ and PyMT;Mtdh/ females
were examined in vivo, tumor incidence (Figure 2H) and volumes
(Figure 2I) were substantially decreased in mice transplanted
with Mtdh/ cells. These results suggest that not only the
expansion, but also the tumorigenic potential of luminal cells is
severely compromised in PyMT;Mtdh/ mice.
We did not detect a selective expansion of either luminal or
basal subset of MECs in MMTV-ErbB2 preneoplastic glands as
compared to normal control (data not shown), in accordance
with a previous report (Shackleton et al., 2006). To identify which
subset of MECs serves as TICs, we sorted out luminal and basal
MECs from ErbB2;Mtdh+/+ hyperplastic glands and orthotopi-
cally transplanted these cells. Palpable tumors were detected
in 100% of the mice that received either luminal or basal MECs
(Figures S2F and S2G). Regardless of cell origin, all tumors
closely resembled spontaneous tumors from MMTV-ErbB2
mice in histology (Figure S2H). These results suggest MMTV-
ErbB2 tumors may originate from both luminal and basal
compartments, and basal cells can give rise to luminal type of
tumors, a finding supported by a recent report (Zhang et al.,
2013a). To identify the cellular targets that are dependent on
MTDH, we also transplanted luminal and basal subsets from
ErbB2;Mtdh/ females in vivo. Strikingly, neither luminal nor
basal ErbB2;Mtdh/ cells gave rise to palpable tumors at the
time when all the mice receiving ErbB2;Mtdh+/+ cells had devel-
oped large tumors (Figures S2F and S2G). These results indicate
that MTDH is critical for maintaining ErbB2-induced basal and
luminal TICs.
In contrast to its essential role in regulating TICs at early tumor-
igenesis, MTDH is largely dispensable for adult MaSCs activities,
as indicated by similar in vivo mammary gland reconstitution
(Figure S2I) efficiency of either unfractionated Lin MECs (Fig-
ure S2J) or MaSCs-enriched basal cells (Figures S2K and S2L)
from WT and KO mice.
MEC-Intrinsic Role of MTDH in Promoting Mammary
Tumor-Initiating Capacities
Because MTDH is widely expressed in mice (Figures 1B and
S1B), the tumorigenesis defects in whole-organism KO mice
could result from either loss ofMTDH inMECs or other cell/tissue
types. To distinguish between these two possibilities, we sought
to re-introduce mouse MTDH specifically in MECs of Mtdh/
mice in vivo and test whether this would rescue the tumorigenic
defects. To this end, we created a MMTV-Mtdh transgenic
mouse line (Figures 3A, S3A, and S3B) and observed expression
of theMtdh transgene specifically in themammary gland, and, toCancer Cell 26, 92–105, July 14, 2014 ª2014 Elsevier Inc. 95
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Figure 2. Mammary Glands from Mtdh–/– Mice Exhibit Defects in Oncogene-Induced Expansion and Tumorigenic Potential
(A) Representative whole mounts (top; scale bar represents 1 mm) and hematoxylin and eosin-stained sections (bottom; scale bar represents 200 mm) of
preneoplastic mammary glands from MMTV-PyMT (4 weeks), MMTV-Wnt (6 weeks), and MMTV-ErbB2 (6 months) mice of the indicated genotypes.
(B) Flow cytometry of CD45CD31TER119 (Lin) MECs from mammary glands of 6-week-old females of the indicated genotypes.
(C and D) Quantification of luminal (C) and basal (D) cells analyzed in (B; n = 4).
(E) Mammosphere formation assays with WT or KO MECs dissociated from preneoplastic glands of MMTV-PyMT (n = 6), MMTV-Wnt (n = 4), and MMTV-ErbB2
(n = 6) mice. Assays performed in triplicate for each mammary gland.
(F) Mammary tumor incidence (left) and size (right) 3 months after orthotopic transplantations of unsorted MECs dissociated from preneoplastic glands of
PyMT;Mtdh+/+ and PyMT;Mtdh/ mice.
(G) Mammary tumor incidence (left) and size (right) 8 weeks after orthotopic transplantations of indicated sorted CD24+CD29low luminal or CD24+CD29high basal
MECs from preneoplastic glands of PyMT;Mtdh+/+ mice.
(H and I) Mammary tumor incidence (H) and volumes (I) 8 weeks after orthotopic transplantations of LinCD24+CD29low luminal cells from preneoplastic glands of
PyMT;Mtdh+/+ and PyMT;Mtdh/ mice.
Statistics: (C–E) Student’s t test. (F–I), tumor incidence based on limiting dilution analysis and tumor volume based onMann-Whitney test. ***p < 0.001, **p < 0.01,
*p < 0.05. Data represent mean ± SEM. See also Figure S2.
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Figure 3. MTDH Is Intrinsically Required for Oncogene-Induced TICs Functionality
(A) Schematic diagram of MMTV-Mtdh transgene construct and breeding scheme used to generate PyMT;Mtdh/ mice with (Mtdh/ +Tg) or without the
MMTV-Mtdh transgene.
(B) MTDH protein levels in PyMT-induced tumors from Mtdh+/+, Mtdh/, or Mtdh/ +Tg mice.
(C) Quantification of CD24+CD29low luminal population in Lin MECs (n = 4) from preneoplastic mammary glands of 6-week-old females of the indicated
genotypes.
(D) Kinetics of mammary tumor onset in MMTV-PyMT females of the indicated genotypes. Mtdh/ (n = 21), Mtdh/ +Tg (n = 20).
(E) Average number of tumor-free mammary glands at indicated ages in the same cohort of mice as in (D).
(F) Tumor burden of same cohorts of mice as in (D).
(G and H) MTDHwas knocked down by two independent shRNA (KD1 and KD2) in freshly dissociated PyMT;Mtdh+/+ pMECs and in vitromammosphere (G; n = 5,
each in triplicate) and in vivo tumor formation assays were performed (H; incidence at 3 months). FC, fold changes.
(I and J) Mouse MTDH was expressed in freshly dissociated PyMT;Mtdh/ pMECs via lentivirus transduction and in vitro mammosphere (I; n = 4, each in
triplicates) and in vivo tumor formation (J) assays were performed.
(K) Schematic diagram of experiments in (L–O).
(L) Mammosphere formation of ALDH+ or ALDH tumor cells from PyMT;Mtdh+/+ tumors.
(M) MTDH was knocked down in sorted ALDH+ cells from PyMT;Mtdh+/+ tumors and mammosphere assays were performed.
(N) Mammosphere formation of LinCD24+CD61+ or LinCD24+CD61 tumor cells from Wnt;Mtdh+/+ tumors.
(O) MTDH was knocked down in sorted LinCD24+CD61+ cells from Wnt;Mtdh+/+ tumors and mammosphere assays were performed.
Statistics: (C, G, I, and L–O) Student’s t test. (D) Log rank test. (E) Chi-square test. (F) Mann-Whitney test. (H and J) Limiting dilution analysis. ***p < 0.001, **p <
0.01, *p < 0.05. Data represent mean ± SEM. See also Figure S3.
Cancer Cell
MTDH-SND1 Interaction in Breast Cancer Initiationa lesser extent, the salivary gland (Figure S3C). Next, we crossed
these MMTV-Mtdh mice with PyMT;Mtdh/ mice to generate
PyMT;Mtdh/ mice with or without exogenousMtdh transgene
(Figure 3A). Notably, transgene (Tg)-rescued PyMT;Mtdh/ tu-mors expressed similar levels of MTDH as that of PyMT;Mtdh+/+
tumors (Figure 3B). We observed a nearly 2-fold increase in the
expansion of luminal cells from PyMT;Mtdh/ +Tg preneo-
plastic glands as compared to PyMT;Mtdh/ mice (Figure 3C).Cancer Cell 26, 92–105, July 14, 2014 ª2014 Elsevier Inc. 97
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Figure 4. SND1 Is Necessary for MTDH-
Mediated Tumor Initiation
(A) Combination of MTDH re-expression and
SND1 knockdown in PyMT;Mtdh/ tumor cells.
The efficiency of SND1 KD and MTDH re-expres-
sion was assessed with western blotting.
(B and C) In vitro mammosphere (B) and in vivo
tumor formation (C; 6 weeks) assays were per-
formed with cells generated in (A). +/ indicate
whether the denoted protein is present (+) or ab-
sent () based on western blotting results in (A).
(D) SND1 was knocked down in PyMT;Mtdh+/+ or
Wnt;Mtdh+/+ pMECs cells and mammosphere
assays were performed in triplicates.
(E and F) Tumor incidence (E) and volume (F) after
orthotopic transplantations of control or SND1-KD
PyMT;Mtdh+/+ pMECs.
Statistics: (B and D) Student’s t test. (C and E)
Limiting dilution analysis. (F) Mann-Whitney test.
***p < 0.001, **p < 0.01, *p < 0.05. Data represent
mean ± SEM. See also Figure S4.
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MTDH-SND1 Interaction in Breast Cancer InitiationIn addition, tumor onset was accelerated (Figure 3D) and tumor
incidence and burden (Figures 3E and 3F) was increased in the
PyMT;Mtdh/ +Tg group. Of note, the presence of the Mtdh
transgene did not alter the histology of the resulting tumors (Fig-
ure S3D). These results strongly support a tumor-intrinsic role of
MTDH in promoting target cell expansion and subsequent mam-
mary tumorigenesis in vivo, although we cannot completely rule
out the contribution of the tumor stroma.
To complement our spontaneous tumor model studies, we
next investigated whether acute manipulation of MTDH also
affects the tumorigeneic potential of preneoplastic MECs. We
knocked down MTDH in pMECs freshly dissociated from
preneoplastic glands of PyMT;Mtdh+/+ (Figure 3G) and ErbB2;
Mtdh+/+ (Figure S3E) females. The sphere-forming capability of
MTDH-knockdown (KD) cells was significantly reduced in multi-
ple independent samples in both models (Figures 3G and S3E).
In vivo tumor formation of PyMT;Mtdh+/+ pMECs was also
severely impaired by MTDH KD (Figure 3H). Conversely, when
MTDH was restored in PyMT;Mtdh/ pMECs via lentivirus
transduction to a level that was comparable to WT counterparts
(data not shown), both in vitro sphere and in vivo tumor formation
were significantly enhanced (Figures 3I, 3J, and S3F–S3H).
We further asked whether TICs from established MTDH-
positive tumors rely on MTDH for their functionality (Figure 3K).
The fact that established tumors from PyMT, Wnt, and ErbB2-
driven tumor models displayed one relatively homogenous
population when profiled with CD24 and CD29 (Vaillant et al.,
2008 and data not shown) highlights the need for other markers
to identify TICs from established tumors. Increased aldehyde
dehydrogenase (ALDH) activity has been found in cancer
stem-like populations in multiple cancer types including breast
cancer (Ginestier et al., 2007), but its use as a TIC marker in
mouse models remains less characterized. We sorted ALDH+
and ALDH cells from PyMT tumors (Figure S3I), and found
that ALDH+ cells exhibited significantly higher in vitro sphere-
forming (Figure 3L) and in vivo tumor-initiating activities (Figures
S3J and S3K) compared to ALDH cells. Consistent with the
ALDH+ population having TIC characteristics, tumors generated
by this population recapitulated the phenotypic heterogeneity of
the initial tumor, with a similar ratio of ALDH+ and ALDH cells98 Cancer Cell 26, 92–105, July 14, 2014 ª2014 Elsevier Inc.(Figure S3L). This indicates that ALDH+ tumor cells are able to
self-renew, as well as to differentiate into ALDH cells. When
MTDH was knocked down in freshly isolated ALDH+ cells from
PyMT;Mtdh+/+ tumors, the sphere-forming activity was signifi-
cantly reduced (Figure 3M). For MMTV-Wnt tumors, the CD61+
population was demonstrated to possess TIC characteristics
and was highly tumorigenic (Vaillant et al., 2008). Consistently,
CD61+ tumor cells were capable of generating a greater number
of tumor spheres than CD61 cells (Figure 3N). Importantly,
MTDH KD compromised the sphere-forming activities in
CD61+ cells from MMTV-Wnt tumors (Figure 3O). These results
suggest that MTDH is continuously required for the full function-
ality of TICs in MTDH-positive tumors.
Protumorigenic Role of MTDH Requires Its Interacting
Partner SND1
We previously identified SND1 as the major binding partner of
MTDH in human breast cancer cells and it had metastasis-
promoting functions similar to MTDH (Blanco et al., 2011). In
this study, we found that the interaction between MTDH and
SND1 was well conserved in human (Figure S4A) and murine
breast cancer cells (Figures S4B–S4D).
To test the necessity of SND1 for the function of MTDH in
tumor initiation, we first knocked down SND1 in PyMT;Mtdh/
tumor cells, and rescued the expression of mouse MTDH
in these cells (Figure 4A). Reintroduction of MTDH in
PyMT;Mtdh/ tumor cells consistently promoted sphere forma-
tion in vitro (Figure 4B) and tumor formation in vivo (Figure 4C);
however, this effect of MTDH was completely abolished upon
SND1 KD (Figures 4B and 4C). If MTDH indeed requires SND1
for its protumorigenic function, we expected knockdown of
SND1 in Mtdh+/+ tumor cells would phenocopy the effect of
MTDH deficiency on mammary tumorigenesis. Indeed, SND1
KD in Mtdh+/+ tumor cells impaired sphere-forming activities
in vitro (Figure 4D) and tumor initiation in vivo (Figures 4E and
4F), resembling the effect of MTDH ablation on tumor initiating
activities. These results together indicate that MTDH’s function
on TICs requires the presence of SND1.
To further test whether the physical interaction with SND1 is
critical for the function of MTDH, we conducted detailed analysis
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Figure 5. Determination of Key Regions and
Residues Mediating the MTDH-SND1 Inter-
action
(A) Schematics of MTDH fragments and mutants
with indicated SND1-binding capability. + in-
dicates binding and  indicates no binding based
on results shown below. Two putative nuclear
localization signals (432–451 for NLS2 and 561–
580 for NLS3) are denoted by green boxes. In the
enlarged view of the minimal binding region 386–
407, nine residues were targeted for mutagenesis
in the current study. Mutations highlighted in red or
purple either completely or strongly reduced the
binding, respectively.
(B) Pulldown of His6-SND1DC by GST-tagged
MTDH fragments with indicated boundaries. The
bound proteins were examined by SDS-PAGE and
depicted with Coomassie blue staining.
(C) Pulldown of His6-SND1DC by GST-tagged WT
or triple mutant MTDH fragments (364–582). For
(B) and (C), one-tenth of the His6-SND1DC input is
shown, and GST alone was used as a negative
control. Representative results of three indepen-
dent experiments are shown.
(D and E) Lysates from HEK293T cells expressing
the indicated ectopic human SND1, AGO2, or
MTDH were immunoprecipitated with anti-Myc
and immunoblotted with the indicated antibodies.
Cancer Cell
MTDH-SND1 Interaction in Breast Cancer Initiationon the interaction. SND1 contains four N-terminal Staphylo-
coccal nuclease (SN) repeats and a C-terminal Tudor-SN hybrid
domain. An SND1 construct missing the C-terminal sequence
following the second SN domain (SND1DC, 1-339) bound
stoichiometrically with MTDH fragment 364–582, but not with
MTDH fragment 1–289 (Figures 5A and 5B), resembling the
binding behavior of full-length SND1 (Blanco et al., 2011). This
allowed us to use the SND1DC fragment for the following
in vitro binding studies. To map the minimal SND1-binding
domain of MTDH, we generated a series of fragments of
MTDH within region 364–582 (Figure 5A) and tested their inter-
action with SND1DC. This led to the identification of a 22 amino
acid fragment (residues 386–407) sufficient for SND1-binding
(Figures 5A and 5B), which was further confirmed by the
crystal structure of the MTDH-SND1 complex (manuscript in
preparation).
To determine key residues of MTDH that are essential for the
interaction, we designed three triple-point mutants (referred to
as TPM) with each harboring three amino acid mutations within
the 22 amino acid minimal binding domain in the MTDH (364–
582) fragment (Figure 5A). In vitro binding assay showed that
both TPM1 and TPM2 could not bind SND1DC whereas TPM3
bound SND1DC as effectively as the WT MTDH (Figure 5C). To
examine whether TPM1 and TPM2 interact with SND1 in vivo,
full-length HA-tagged SND1 and Myc-tagged MTDH were
ectopically expressed in HEK293T cells and the cell lysates
were subjected to anti-Myc immunoprecipitation. Consistent
with the findings from in vitro binding assays (Figure 5C), HA-
SND1 was pulled down with WT but not TPM1 or TPM2 MTDH
(Figure 5D). We further analyzed all nine individual mutations
using similar strategies and found that W394D completely andW401D partially abolished the binding, whereas other mutations
individually did not affect the interaction (Figure 5E). SND1-
binding deficient TPM1 and TPM2 MTDH were still able to
interact with AGO2 (Figure 5D), another known binding partner
of MTDH (Yoo et al., 2011), suggesting that these mutations
are unlikely to cause gross conformational changes in MTDH,
but rather selectively disrupt the interaction with SND1.
We next tested whether these mutations affect MTDH’s func-
tion in tumorigenesis. We first stably expressed themurine forms
of WT MTDH, TPM1, or TPM2 in PyMT;Mtdh/ tumor cells and
found that these MTDH mutants lost the ability to interact with
SND1 (Figure 6A). Functionally, WT MTDH was able to increase
sphere-forming activities of PyMT;Mtdh/ cells in vitro and
tumor initiation in vivo, whereas TPM1 or TPM2 mutants failed
to do so (Figures 6B–6D). Similar results were observed when
the W391D mutant (corresponding to W394D in human MTDH)
was tested (Figures 6E–6H). These results strongly suggest
that binding residues of MTDH with SND1 are highly conserved
in human and mice, and the interaction with SND1 is critical for
mediating the functionality of MTDH in regulating TICs activities.
MTDH-Mediated Stabilization of SND1 Confers MECs
Survival Advantage under Stress Conditions
SND1 has been reported as a survival factor under various stress
conditions (Gao et al., 2010; Sundstro¨m et al., 2009; Weissbach
and Scadden, 2012). The more prominent role of MTDH in tumor
initiation but not normal physiology of mammary glands led us
to hypothesize that MTDH, through its interaction with SND1,
confers MECs survival advantages under stress conditions dur-
ing tumorigenesis. Supporting this hypothesis, we detected a
significantly higher percentage of apoptotic cells in preneoplasticCancer Cell 26, 92–105, July 14, 2014 ª2014 Elsevier Inc. 99
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Figure 6. SND1-Binding-Deficient MTDH Fails to Promote Tumor-Initiating Potential of MECs
(A and E) Lysates from PyMT;Mtdh/MECs reconstituted with vector control, WT or mutant murine MTDH were immunoprecipitated with anti-MTDH antibody
and immunoblotted for indicated proteins.
(B and F) Mammosphere assays were performed with PyMT;Mtdh/ pMECs reconstituted with indicated Mtdh constructs.
(C, D, G, and H) In vivo tumor formation (C and G for tumor incidence; D and H for tumor volumes) were performed at limiting numbers using PyMT;Mtdh/
pMECs reconstituted with indicated WT or mutant MTDH. *Note: mouse W391D MTDH corresponds to human W394D MTDH; and mouse W398D MTDH
corresponds to human W401D MTDH.
Statistics: (B and F) Student’s t test. (C and G) Limiting dilution analysis. (D and H) Mann-Whitney test. Data represent mean ± SEM. ***p < 0.001, **p < 0.01,
*p < 0.05.
Cancer Cell
MTDH-SND1 Interaction in Breast Cancer InitiationPyMT;Mtdh/ mammary epithelium than in PyMT;Mtdh+/+
counterparts, which was not seen in glands without PyMT (Fig-
ure 7A). To test the role of MTDH-SND1 interaction under stress
conditions in vitro, we treated PyMT;Mtdh/ pMECs, reconsti-
tuted with either WT or mutant mouse MTDH, with camptothecin
(CPT) to induce DNA replication stress (Figure 7B), a common
type of stress during tumor development (Halazonetis et al.,
2008). CPT treatment induced apoptosis of MECs in a dosage-
dependent manner (Figure 7B). There was a significantly
decreased percentage of apoptotic cells in the MTDH-rescued
group compared to that in control, and SND1-binding deficient
mutations ablated this prosurvival effect of MTDH (Figure 7B).
Consistent with the previous observation that SND1 levels are
critical for cell survival under stress conditions, silencing of SND1
in PyMT;Mtdh+/+ MECs led to a significant increase in apoptosis
upon CPT treatment (Figure 7C). Interestingly, we observed a
drug dosage-dependent decrease of SND1 protein levels in
MECs treated with CPT (Figure 7D). This phenomenon was not
unique to this type of stress, as heat shock treatment also re-
sulted in rapid decrease of SND1 (Figure S5). Notably, silencing
of MTDH in PyMT;Mtdh+/+ pMECs accelerated the decrease of
SND1 protein (Figure 7D). Conversely, restoration of WT, but
not SND1-binding deficient MTDH, in PyMT;Mtdh/ MECs
stabilized SND1 protein under these stress conditions (Figures
7E and S5). Thus, these data collectively suggest that MTDH
promotes survival under stress conditions by interacting with
and stabilizing survival factor SND1.
To provide a better understanding of how SND1 exerts its
prosurvival function, we performed transcriptomic profiling of
control versus SND1-KD PyMT;Mtdh+/+ pMECs under CPT
treatment (Figures 7F–7H). Ingenuity Pathway Analysis revealed100 Cancer Cell 26, 92–105, July 14, 2014 ª2014 Elsevier Inc.that genes upregulated by SND1 (Figure 7F, > 2-fold change, p <
0.05) showed a significant enrichment for molecular and cellular
functions including ‘‘cell death and survival,’’ ‘‘cell cycle,’’ and
‘‘DNA repair’’ (Figure 7G), processes related to CPT-induced
replication stress. Notably, a significant portion of SND1-upre-
gulated genes were implicated in the ‘‘cell death and survival’’
category and the expression of these genes collectively was pre-
dicted to significantly activate cell viability function (Figure 7H,
red) and compromise cell death and apoptosis (Figure 7H,
green). Therefore, the ability of SND1 to globally activate prosur-
vival genes may underlie its role in protecting cells from stress-
induced cell death (Figure 7C). To substantiate the hypothesis
that MTDH regulates survival through interacting with and stabi-
lizing SND1, we profiled PyMT;Mtdh/ pMECs reconstituted
with either WT or SND1-binding deficient mutant mouse MTDH
(W391D). Gene set enrichment analysis demonstrated that
SND1-upregulated gene signature was significantly enriched in
PyMT;Mtdh/ pMECs reconstitured with WT versus mutant
MTDH (Figure 7I).
MTDH and SND1 Are Important for Tumor-Initiating
Activities of Human Breast Cancer Cells
To demonstrate the important roles of both MTDH and SND1 in
tumor-initiating activities in human breast cancer, we silenced
MTDH or SND1 in multiple human breast cancer models,
including: (1) HER2/Neu-transformed human breast epithelial
cells (HMLE-N; Mani et al., 2008; Figures 8A, 8B, S6A, and
S6B), (2) human primary patient-derived xenografts (DeRose
et al., 2011; Zhang et al., 2013b; Figures 8C, 8D, S6C, and
S6D; data not shown), and (3) the MDA-MB-231 human breast
cancer cell line (Figures 8E–8H). Knockdown of either MTDH or
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Figure 7. MTDH Confers Survival Advantage by Interacting with and Stabilizing Pro-Survival Protein SND1 under Stress
(A) Quantification of cleaved caspase 3-positive MECs from normal or MMTV-PyMT preneoplastic glands (n > 3) of WT or KO females.
(B) The effect of CPT on the apoptosis of PyMT;Mtdh/ pMECs reconstituted with indicated Mtdh constructs was determined by PI and Hoechst staining.
(C) The effect of CPT on the apoptosis of control or SND1-KD PyMT;Mtdh+/+ pMECs.
(D) Protein levels of SND1 and b-actin (loading control) in control or MTDH-KD PyMT;Mtdh+/+ pMECs treated with CPT at indicated concentrations for 36 hr.
Degradation curve (right) represents the average of three independent experiments.
(E) Western blotting of SND1, MTDH, and b-actin (loading control) in PyMT;Mtdh/MECs reconstituted with indicated constructs after CPT treatment for 48 hr.
Degradation curves (right) represent average of three independent experiments.
(F) Heat map representation of microarray data displaying the expression of SND1-upregualted genes (n = 504, fold change > 2, p < 0.05) in control versus SND1-
KD PyMT;Mtdh+/+ pMECs under CPT (50 mM) treatment for 36 hr. Color key indicates log2 values.
(G) Ingenuity pathway analysis shows the top five molecular and cellular functions of SND1-upregulated genes shown in (F) and the number of molecules/genes
implicated in each category.
(H) Effects of SND1-upregulated genes in cell survival and cell death functions. Z scores were calculated based on gene expression changes and gene functions
as specified by the ingenuity knowledge base. A given function is predicted to be significantly increased when z > 2 or decreased when z < 2.
(I) Gene set enrichment analysis plot showing the enrichment of SND1-upregulated gene signature in PyMT;Mtdh/ MECs rescued with mouse WT MTDH as
compared to those rescued with W391D mutant MTDH. All cells were treated with CPT (50 mM). NES, normalized enrichment score.
Statistics: (A–C) Student’s t test. Data represent mean ± SEM. ***p < 0.001, **p < 0.01, *p < 0.05. See also Figure S5.
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Figure 8. MTDH and SND1Are Important for
In Vitro Sphere-Forming and In Vivo Tumor-
Initiating Activities of Human Breast Cancer
Cells
(A and B) MTDH (A) or SND1 (B) was knocked
down in HMLE-Neu cells and tumorsphere assays
were performed in triplicate.
(C and D) MTDH (C) or SND1 (D) was knocked
down in the BCM-4013 patient-derived xeno-
grafted (PDX) tumor cells and tumorsphere assays
were performed in triplicate.
(E) MTDH or SND1 was knocked down in
MDA-MB-231 cells, and the KD efficiency was
measured by immunoblotting.
(F) Tumorsphere assays of MDA-MB-231 cells
were performed in triplicate.
(G and H) Tumor incidence (G) and volumes (H)
5 weeks after injection of limiting numbers of
MDA-MB-231 cells.
(I) The protein levels of MTDH and SND1 in human
invasive mammary carcinomas (n = 154) were
determined by IHC staining of a breast cancer
tissue microarray (BR1921a, US Biomax). The
staining intensity in tumor cells was scored as
0 (negative), 1 (weak), 2 (moderate), or 3 (strong).
(J) Bar graph presentation of (I).
(K) Representative tumor specimens with strong
(tumor 1), weak (tumor 2), and negative (tumor 3)
staining of MTDH and SND1. Scale bar represents
200 mm (top) and 20 mm (bottom) for each tumor.
(L) Schematic illustration depicting the essential
role of MTDH in tumor initiation but not normal
gland development. Under stress conditions dur-
ing tumorigenesis, the MTDH-SND1 interaction
protects SND1 from stress-induced degradation
and supports the survival and activities of both
basal and luminal TICs.
Statistics: (A–D and F) Student’s t test. (G) Limiting
dilution analysis. (H) Mann-Whitney test. (I and J)
Chi-square test. Data represent mean ± SEM.
***p < 0.001, **p < 0.01, *p < 0.05. See also Fig-
ure S6.
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models tested and tumor initiation of MDA-MB-231 cells in vivo.
We further examined whether MTDH-mediated stabilization of
SND1 occurs in human breast cancer samples. We stained a
human breast cancer tissue microarray (TMA) with antibodies
against MTDH and SND1 (Figures 8I-8K), after confirming the
specificity of the antibodies (Figures S6E and S6F). We found a
positive correlation between staining scores of MTDH and
SND1 (Figures 8I and 8J), which was confirmed using an inde-
pendent TMA (Figures S6G and S6H). Of note, MTDH and
SND1were not correlated at the mRNA levels (Figure S6I). These
data support a key role of MTDH in posttranscriptional regulation
of SND1 in breast cancer, consistent with our findings thatMTDH
interacts with and stabilizes SND1 under stress conditions dur-
ing tumorigenesis.
To further explore the clinical importance of the MTDH-SND1
interaction, we analyzed the NKI295 human breast cancer
microarray data set (van de Vijver et al., 2002). We stratified
patients into four different groups based on median expression
for bothSND1 andMTDH. Primary tumorswith highmRNA levels
of both MTDH and SND1 were significantly larger (Figure S6J),102 Cancer Cell 26, 92–105, July 14, 2014 ª2014 Elsevier Inc.less differentiated (Figure S6K), and correlated with a shorter
distant metastasis-free survival (Figure S6L), supporting a func-
tional cooperation between MTDH and SND1 in human breast
cancer in tumor development, metastasis, and recurrence.
Consistent with its tumor-promoting function in diverse mam-
mary tumor models, we further found that higher levels of
MTDH predicted poor prognosis across multiple breast cancer
subtypes in the KM-plotter data set (Figure S6M). The seemingly
stronger prognostic power ofMTDH in luminal A subtype is likely
due to a significantly larger sample size in this group compared
to other subtypes.
DISCUSSION
Whereas the classical clonal evolution theory of tumor progres-
sion postulates that metastatic capabilities are endowed by
random genetic changes occurring in rare cells within the
primary tumor, genomic and clinical studies paradoxically
demonstrate that the likelihood to metastasize can be predicted
by profiling the bulk of primary tumors (van de Vijver et al., 2002).
This suggests metastatic potential may be conferred by
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functions (Bernards and Weinberg, 2002), and therefore these
genetic changes can occur and be selected early in tumor evo-
lution (Vanharanta andMassague´, 2013). Supporting this notion,
several metastasis-promoting genes have been shown to pro-
mote primary tumor growth in xenograft models (Vanharanta
and Massague´, 2013; Wan et al., 2013). The recurrent amplifica-
tion/overexpression of MTDH in human primary breast tumors
may therefore implicate MTDH in tumorigenesis in addition
to its reported role in promoting breast cancer metastasis.
Whereas previous studies using human or murine breast cancer
cell lines failed to reveal any effect of MTDH on primary tumor
formation in xenograft models (Brown and Ruoslahti, 2004; Hu
et al., 2009), genetically engineered mouse models used in this
study enabled us to uncover a role of MTDH in regulating the
expansion and activities of TICs at early stages of tumorigenesis,
thus establishing another molecular link between primary tumor
initiation with the acquisition of metastatic traits. This effect of
MTDH on tumor initiation has likely been masked when a large
number of highly aggressive and late-stage tumor cells were
used in previous xenograft studies. Consistent with this specula-
tion, when late-stage PyMT tumor cells were transplanted in
large quantities, we failed to observe a difference in tumor initia-
tion betweenMtdhWT and KO cells (data not shown). Neverthe-
less, TICs from MTDH-positive established mammary tumors,
such as ALDH+ cells and CD61+ cells from PyMT and Wnt-
induced tumors, respectively, remain sensitive to MTDH inhibi-
tion, suggesting that MTDH-dependent mechanisms are at
play in established tumors to maintain the optimal functionality
of TICs, and therefore blocking MTDH and its regulated path-
ways will be beneficial to cancer patients with aberrant expres-
sion of MTDH.
It has been suggested that initiating genetic lesions exert a sig-
nificant influence on the histopathology and molecular features
of mammary tumors from both humans and transgenic animals.
For example, Wnt signaling induces mammary tumors with fea-
tures resembling more primitive progenitor cells as compared to
PyMT and ErbB2 (Li et al., 2003). Remarkably, we found that
MTDH is required for the functionality of TICs across these
different tumor models. Consistently, MTDH expression does
not significantly correlate with specific subtypes of human breast
cancer (Hu et al., 2009) and higher levels of MTDH predict poor
prognosis across different subtypes. These results together
corroborate the idea that MTDH promotes tumor initiation in an
oncogene- and lineage-independent manner, in contrast to line-
age-specific tumor-promoting genes, such as luminal tumor sur-
vival factor PDEF (Buchwalter et al., 2013). The broad function of
MTDH in tumorigenesis is also in agreement with its frequent up-
regulation in a diverse spectrum of cancer types (Emdad et al.,
2013; Wan and Kang, 2013).
Tumors formed in the absence of MTDH exhibited similar
histological features as MTDH-positive tumors, suggesting that
MTDH may not alter the cell of origin or cell fate of TICs, but
instead influence their tumorigenic potential. This, together
with the observation that Mtdh KO had little effect on the activ-
ities of MaSCs, establish MTDH as a critical regulator of TICs
that is distinct from other cell fate regulators, such as Wnt
signaling (Lento et al., 2013), Slug/Sox9 (Guo et al., 2012), and
GATA3 (Kouros-Mehr et al., 2008), which regulate tumorigenesisby virtue of their abilities to mediate the conversion between
differentiated cells and more primitive stem/progenitor cells in
both normal and malignant contexts.
We and others have identified SND1 as a major binding part-
ner of MTDH (Blanco et al., 2011; Meng et al., 2012; Yoo et al.,
2011). However, a discrepancy exists regarding the binding
domains of MTDH with SND1, because two nonoverlapping
regions of MTDH, namely amino acids 364–470 (Blanco et al.,
2011) and 101–205 (Yoo et al., 2011), were each independently
mapped as the only essential domain mediating MTDH’s inter-
action with SND1. Our study further determines a minimal
fragment of MTDH (386–407) sufficient for the interaction and
identifies two key residues within this fragment critical for the
interaction. These findings enabled us to demonstrate that the
interaction with SND1 is pivotal for the function of MTDH. These
findings also establish SND1 as a critical regulator of mammary
TICs. Importantly, the interaction between MTDH and SND1 as
well as the binding residues are well conserved between human
and mice, highlighting the possibility that our findings in mouse
models may be highly relevant to human cancer, as suggested
by the current functional and clinical analyses.
Tumorigenesis is accompanied by diverse stresses that
tumor cells have to overcome, including oncogene-induced
DNA replication/damage stress. We demonstrated that SND1
is required for the expression of a cohort of prosurvival genes
in cells under stress conditions, and silencing of SND1
sensitizes transformed MECs to replication stress-induced
apoptosis. These results are consistent with previous reports
that established SND1 as a prosurvival protein under various
stress conditions (Gao et al., 2010; Sundstro¨m et al., 2009;
Weissbach and Scadden, 2012). Furthermore, the physical
interaction with MTDH is essential to protect SND1 from degra-
dation and sustain SND1-regulated gene signature under stress
conditions. It is thus possible that MTDH protects TICs from
attritions under stress conditions during tumorigenesis, at least
in part, by virtue of its ability to interact with and stabilize SND1
(Figure 8L). It remains unclear how SND1 regulates downstream
prosurvival genes. SND1 is a multifunctional protein that has
been reported to be involved in several gene regulatory pro-
cesses, including transcriptional control, mRNA splicing, RNA
stress granule formation, and RNA-induced silencing complex
(RISC) machinery (reviewed in Wan and Kang, 2013). Future
studies are warranted to investigate how SND1 modulates
gene expression in response to stress conditions to promote
cellular survival.
In addition to providing a molecular link between tumor initia-
tion and metastatic capabilities, our findings suggest several
lines of potential translational applications. First, the functional
importance of MTDH and SND1 in sustaining TIC function, if
extensively validated in patient-derived tumor grafts, may estab-
lish these proteins as potential therapeutic targets in cancer
treatment. In addition, our results on the MTDH-SND1 interac-
tion may facilitate the screening or design of small molecule in-
hibitors that can disrupt the interaction of MTDH and SND1.
Our results also highlight the tumor-specific requirement of
MTDH and suggest that systemic targeting of the MTDH-SND1
module may be well tolerated by cancer patients, as whole or-
ganism knockout of Mtdh does not cause significant defects in
mice. Future studies are needed to fully assess the therapeuticCancer Cell 26, 92–105, July 14, 2014 ª2014 Elsevier Inc. 103
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progression.
EXPERIMENTAL PROCEDURES
Mice
All experimental protocols involving mice were approved by Institutional
Animal Care and Use Committee of Princeton University. Mtdh-KO mice
were generated by injecting ES cell line XB780 (BayGenomics) into the
C57BL/6 blastocysts followed by confirmation of germline transmission. KO
micewere then backcrossed to FVB background for more than six generations
before breeding with MMTV-PyMT, MMTV-ErbB2, MMTV-Wnt transgenic
mice (Jackson Laboratory) in FVB background. To create the MMTV-Mtdh
construct, the mouse Mtdh coding sequence was inserted into the pMMTV-
SV40 vector, then the expression cassette was linearized and microinjected
into the pronuclei of zygotes from FVB mice. For spontaneous tumorigenesis
studies, female mice carrying the specific oncogenes were examined weekly
for mammary tumors. Tumors were considered established when they
became palpable for 2 consecutive weeks, and tumors were measured by
calipers for calculation of tumor volumes (p 3 length 3 width2/6). Lung
nodules were counted directly after fixation (MMTV-PyMT models) or after
sectioning and staining of the lungs (MMTV-ErbB2 model).
Human Breast Cancer TMAs
Two human breast TMAs were used in the study to examine the correlation of
MTDH and SND1 protein levels. One TMA was purchased from US Biomax
(BR1921a) and a second TMA was obtained from the Cancer Institute of
New Jersey (YMTA_201). Both sets of TMAs used de-identified tumor samples
and were considered exempt by the Institutional Review Boards of Princeton
University and the Rutgers New Jersey Medical School.
Harvesting Mammary Epithelial Cells and Flow Cytometry
Single cell suspensions of mammary glands or tumors were prepared as pre-
viously described (Shackleton et al., 2006). Briefly, tissues were dissected,
minced into small pieces and digested for 1 hr at 37C in culture medium
(1:1 Dulbecco’s modified Eagle’s medium [DMEM]: Ham’s F-12 medium
containing 5% FBS, 10 ng/ml epidermal growth factor [EGF], 500 ng/ml hy-
drocortisone, 5 mg/ml insulin, 20 ng/ml cholera toxin, and 1% Pen/Strep)
supplemented with 300 U/ml type 1A collagenase (Sigma) and 100 U/ml hyal-
uronidase (Sigma). Organoids were sequentially suspended with 0.25%
trypsin-EDTA for 1.5 min, 5 mg/ml Dispase (Invitrogen), and 0.1 mg/ml DNase
(Sigma) for 5 min, and 0.64% ammonium chloride for 5 min at 37C before
filtration through a 40 mm nylon cell strainer and antibody staining. Mammary
epithelial cells were incubated with an antibody cocktail containing CD31,
CD45, TER119, CD24, CD29, and CD61 for 30min followed by secondary anti-
body staining for 20 min before FACS analysis or sorting.
Limiting Dilution Assays
For mammary gland reconstitution assays, single cell suspensions of MECs
from mammary glands of 7- or 8-week-old female mice were sorted and
injected into clearedmammary fat pads of 3-week-old recipient mice. The out-
growths were analyzed at 6–8 weeks after transplantation. For tumorigenesis
assays, single cell suspensions of primary MECs were transplanted into FVB
WT recipient mice unless otherwise indicated.
Mammosphere/Tumorsphere Assays
Single cells were plated in ultralow attachment plates (Corning) with sphere
media (1:1 DMEM: Ham’s 12 supplemented with B27 [Invitrogen], 20 ng/ml
EGF [Novoprotein], 20 ng/ml basic fibroblast growth factor, and 4 mg/ml hep-
arin). Spheres were counted 4–7 days after plating.
Microarray Analysis
RNA was extracted from indicated tumor cells under CPT (50 mM) treatment
and analyzedwith AgilentWholeMouseGenome 43 44k arrays. RNA samples
were labeled with Cy5 using the Agilent Low RNA Input Linear Amplification Kit
and hybridized along with the Cy3-labeled Mouse Universal Reference RNA
(Stratagene). Arrays were scanned with an Agilent G2565BA scanner and104 Cancer Cell 26, 92–105, July 14, 2014 ª2014 Elsevier Inc.analyzed with the Agilent Feature Extraction v9.5 software. The Cy5/Cy3 ratios
were calculated using the feature medium signal and normalized by the array
median. Genes with > 2-fold (average) changes and Student’s t test p values <
0.05 were included as SND1-regulated genes.
Statistical Analysis
All results wherever necessary were subjected to statistical analysis. A log-
rank test, a nonparametric Mann-Whitney test, Chi-square test, and unpaired,
two-sided, independent Student’s t test with equal variance assumption were
used for most studies as indicated in the figure legends. For limiting dilution
assay, the frequency of MaSCs or TICs and statistics were calculated using
L-calc software (StemCell Technologies). The p values were denoted as *p <
0.05, **p < 0.01, and ***p < 0.001 in all figures.
ACCESSION NUMBERS
The Gene Expression Ominibus accession number for all raw microarray data
files is GSE55522.
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